Tocilizumab reduces hypercoagulation in COVID-19 - Perspectives from the coagulation and immunomodulation Covid assessment (Coag-ImmCovA) clinical trial.

Lou M AlmskogAnna SjöströmJonas Sundén-CullbergApostolos TaxiarchisAnna ÅgrenSara FreylandMadeleine BörjessonAgneta WikmanCarl Magnus WahlgrenMichael WanecekJan van der LindenJovan AntovicJon LampaMaria Magnusson

Published in: Thrombosis research (2024)

Tocilizumab treatment demonstrated a significant reduction of hypercoagulation in hospitalized COVID-19 patients, by improvements in both global coagulation tests and conventional laboratory tests, in comparison with anakinra or SC alone. This finding underscores the significance of tocilizumab as a viable treatment option in severe COVID-19 cases, with the potential to decrease thrombosis incidence.

Keyphrases

sars cov
coronavirus disease
rheumatoid arthritis
clinical trial
juvenile idiopathic arthritis
rheumatoid arthritis patients
randomized controlled trial
pulmonary embolism
respiratory syndrome coronavirus
combination therapy
early onset
replacement therapy
study protocol
phase ii
drug induced